Micardis® / MicardisPlus® Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases (PROTEKT)

Completed

• Conditions: Hypertension
• Interventions: Drug: Micardis®; Drug: MicardisPlus®

• Registration Number: NCT02262637
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

Study to evaluate efficacy and tolerability of Micardis®/MicardisPlus® under usual daily-practice prescribing-conditions with emphasis on effects on endorgan damage in the clientele of cardiologists, nephrologists, and diabetologists

Detailed Description

Not available

Study Timeline

• Study Start: 2003-09
• Primary Completion: 2006-03
• Status Verified: 2014-10
• Study First Submitted: 2014-10-10
• Study First Submitted QC: 2014-10-10
• Last Update Submitted: 2014-10-10
• Study First Posted: 2014-10-13
• Last Update Posted: 2014-10-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 4814

Inclusion Criteria

• Age >= 18 years

Read More

Exclusion Criteria

• Age < 18 years

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Hypertensive patients - Nephrologists	Micardis®	-
Hypertensive patients - Cardiologists	Micardis®	-
Hypertensive patients - Cardiologists	MicardisPlus®	-
Hypertensive patients - Diabetologists	Micardis®	-
Hypertensive patients - Diabetologists	MicardisPlus®	-
Hypertensive patients - Nephrologists	MicardisPlus®	-

Primary Outcome Measures

Name	Time	Method
Change in systolic blood pressure (SBP)	baseline, up to 6 months
Change in diastolic blood pressure (DBP)	baseline, up to 6 months